Starpharma completes chairman succession


By Dylan Bushell-Embling
Monday, 16 June, 2014

Starpharma’s (ASX:SPL) long-serving chairman Peter Bartels has retired from his role and been replaced with chair-elect Rob Thomas.

Bartels has been non-executive chairman of Starpharma since 2003. He announced his decision to retire in November last year as part of a board succession plan.

Thomas joined the company the following month as non-executive director and chair-elect. He has had more than 35 years of experience in the financial services sector at Potter Partners (now UBS), County Natwest and Citigroup.

Thomas is currently a non-executive director in healthcare companies including Heartware International, Biotron (ASX:BIT) and REVA Medical (ASX:RVA). He was the former non-executive chairman of Heartware International.

In a statement announcing the change of guard, the Starpharma board said Bartels had played a major role in transforming the company into a business with multiple products near commercial launch.

“I have had the pleasure of working beside Peter over the last six months and I take over as chairman at a time when the fundamentals of the Starpharma business are strong,” Thomas commented.

Starpharma (ASX:SPL) shares were trading 1.67% higher at $0.61 as of around 1 pm on Monday.

Related News

Cancer drug eliminates bone metastasis in lab models

Researchers have developed a novel treatment that is specific to breast cancer bone metastasis...

TGA rejects Alzheimer's drug due to safety concerns

The TGA determined that the demonstrated efficacy of lecanemab in treating Alzheimer's did...

Defective sperm doubles pre-eclampsia risk in IVF patients

A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd